Research

Emma Guttman

NAAF Applauds NIH Award to Mount Sinai for Alopecia Areata Research

The National Alopecia Areata Foundation applauds the announcement that the National Institutes of Health (NIH) has awarded a $6.6 million…

NAAF Team Attends American Academy of Dermatology Meeting in San Diego

Members of the NAAF team represented the organization and the alopecia areata patient community at the 2024 Annual Meeting of…

Dr. Lindsay Criswell

NIAMS Leadership Meets with NAAF

Key leaders of the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) met with NAAF President & CEO,…

NAAF Grants: Student Internship Awards and Travel Grant Applications Now Open

Applications for Student Internship Awards for 2024 are now open. These awards support students (undergraduate, graduate, or medical), residents, or…

Puzzle pieces with medical terms like clincal trial

Alopecia Areata Research Depends on Clinical Trial Volunteers

Media reports of two newly approved drugs for treating alopecia areata brought good news to many people living with the…

researcher looking at a microscope

Zura Bio Joins NAAF’s 2023 Industry Partner Program

NAAF is pleased to announce that Zura Bio has joined the Industry Partner Program at the Bronze membership level. Zura…

FDA Approves LITFULO™ (Ritlecitinib) for Adults and Children ages 12+ with Severe Alopecia Areata

Today, the U.S. Food and Drug Administration (FDA) approved LITFULO™ for severe alopecia areata, marking the second FDA-approved treatment for…

volunteer hands 2

New Research: Prevalence of Alopecia Areata across Races and Ethnicities

Does alopecia areata (AA) affect all races and ethnic groups equally? If yes, why is this important? Knowing AA prevalence…

New Clinical Trial Data Published for Ritlecitinib

Results from a clinical trial for a new treatment for alopecia areata were published in the medical journal The Lancet…

Treatment Development Program Impact Report

As we come to the close of 2022, we look upon these past 12 months as among the most pivotal…